Back

ESMO-BC-I 2020 - ESMO Breast Cancer Annual Congress (Virtual Meeting)

May 23 - May 24, 2020 | BerlinGermany

LARVOL is not affiliated with ESMO Breast Cancer Annual Congress (Virtual Meeting) and all trademarks, logos, and brand names are property of their respective owners

Top Trials
Top Trials has no data

Showing 98 abstracts linked to Trials

4P - [VIRTUAL] Independent validation of the PAM50-based chemoendocrine score (CES) as pathologic complete response (pCR) and disease-free survival (DFS) predictor in hormone receptor (HR)+/HER2+ breast cancer (BC)

  • E-Poster

6P - [VIRTUAL] Circulating tumour cells (CTCs) as biomarkers of resistance to the CDK4/6 inhibitor (CDK4/6i) palbociclib (P) in patients (pts) with ER+/HER2-negative advanced breast cancer (ABC)

  • E-Poster

7P - [VIRTUAL] Prognostic value of the immune infiltration score in early breast cancer patients receiving dual HER2 blockade with trastuzumab and pertuzumab: An exploratory analysis of a randomized clinical trial

  • E-Poster

8P - [VIRTUAL] Characterization of immune microenvironment before and following anti-HER2 neoadjuvant therapy (NAT)

  • E-Poster

12P - [VIRTUAL] Gene expression profiling in early breast cancer treated with neoadjuvant ribociclib plus letrozole (R+L) versus chemotherapy (CT): A correlative analysis of the SOLTI-1402/CORALLEEN phase II trial

  • E-Poster